A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs

AIM: We evaluated the relationship between liraglutide and acute pancreatitis or pancreatic cancer in an ongoing post-marketing safety assessment programme. METHODS: Initiators of liraglutide, exenatide, metformin, pioglitazone or groups containing initiators of dipeptidyl peptidase-4 inhibitors or...

Descripción completa

Detalles Bibliográficos
Autores principales: Funch, D, Gydesen, H, Tornøe, K, Major-Pedersen, A, Chan, K A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237552/
https://www.ncbi.nlm.nih.gov/pubmed/24199745
http://dx.doi.org/10.1111/dom.12230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237552/
https://www.ncbi.nlm.nih.gov/pubmed/24199745
http://dx.doi.org/10.1111/dom.12230

Ejemplares similares